Literature DB >> 16245160

Gonadal effects of a mouse Denys-Drash syndrome mutation.

C E Patek1, P T K Saunders, C G Miles, R L Berry, N D Hastie, R M Sharpe, M L Hooper.   

Abstract

Gonadal effects of the Denys-Drash syndrome (DDS) mutation Wt1(tmT396 )were examined in chimaeric and heterozygous mice. Since the only heterozygote was 41,XXY, Sertoli cell function was assessed by comparison with age-matched control XXY testes. Control XXY Sertoli cells showed immuno-expression of WT1 and androgen receptor (AR) indistinguishable from wild-type (40,XY), but expressed anti-Mullerian hormone (AMH). In contrast, DDS Sertoli cells showed only faint immuno-expression of WT1 and did not express AR or AMH. While XY<-->XY DDS chimaeras were male, XX<-->XY chimaeras were predominantly female. In the rare XX<-->XY DDS males the Sertoli cell lineage was largely derived from Wt1 mutant XY cells. We conclude that DDS mutant cells can form Sertoli cells, that the dominant mutation does not cause male sex reversal in mice but distorts the sex ratio of XX<-->XY chimaeras, and that there may be a link between WT1, AMH and AR expression by Sertoli cells in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16245160     DOI: 10.1007/s11248-005-7216-y

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  33 in total

1.  Number of chromocentres in the nuclei of mouse Sertoli cells in relation to the strain and age of males from puberty to senescence.

Authors:  H Krzanowska; B Bilińska
Journal:  J Reprod Fertil       Date:  2000-03

Review 2.  Clinical and molecular evidence for the role of androgens and WT1 in testis descent.

Authors:  H N Lim; I A Hughes; J R Hawkins
Journal:  Mol Cell Endocrinol       Date:  2001-12-20       Impact factor: 4.102

3.  Wilms' tumor 1 and Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression.

Authors:  M W Nachtigal; Y Hirokawa; D L Enyeart-VanHouten; J N Flanagan; G D Hammer; H A Ingraham
Journal:  Cell       Date:  1998-05-01       Impact factor: 41.582

4.  WT-1 is required for early kidney development.

Authors:  J A Kreidberg; H Sariola; J M Loring; M Maeda; J Pelletier; D Housman; R Jaenisch
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

5.  Germ cell loss in the XXY male mouse: altered X-chromosome dosage affects prenatal development.

Authors:  P A Hunt; C Worthman; H Levinson; J Stallings; R LeMaire; K Mroz; C Park; M A Handel
Journal:  Mol Reprod Dev       Date:  1998-02       Impact factor: 2.609

Review 6.  Gonadal development in mammals at the cellular and molecular levels.

Authors:  S Mackay
Journal:  Int Rev Cytol       Date:  2000

7.  Bilateral Wilms tumor in a boy with severe hypospadias and cryptochidism due to a heterozygous mutation in the WT1 gene.

Authors:  B Köhler; V Schumacher; U Schulte-Overberg; W Biewald; T Lennert; D l'Allemand; B Royer-Pokora; A Grüters
Journal:  Pediatr Res       Date:  1999-02       Impact factor: 3.756

8.  The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Müllerian-inhibiting substance, and the androgen receptor.

Authors:  R Shimamura; G C Fraizer; J Trapman; G F Saunders
Journal:  Clin Cancer Res       Date:  1997-12       Impact factor: 12.531

9.  Müllerian-inhibiting substance function during mammalian sexual development.

Authors:  R R Behringer; M J Finegold; R L Cate
Journal:  Cell       Date:  1994-11-04       Impact factor: 41.582

10.  Purified bovine AMH induces a characteristic freemartin effect in fetal rat prospective ovaries exposed to it in vitro.

Authors:  B Vigier; F Watrin; S Magre; D Tran; N Josso
Journal:  Development       Date:  1987-05       Impact factor: 6.868

View more
  1 in total

1.  Androgen action via testicular peritubular myoid cells is essential for male fertility.

Authors:  Michelle Welsh; Philippa T K Saunders; Nina Atanassova; Richard M Sharpe; Lee B Smith
Journal:  FASEB J       Date:  2009-08-19       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.